The study on the treatment of chronic kidney disease iii in Dagle net was successfully terminated early

March 30, AstraZenecom announced the early termination of the Phase III DAPA-CKD study on the treatment of chronic kidney disease in Dagley net, as recommended by the Independent Data Monitoring Board.The DAPA-CKD study included 4,245 patients with stage II-IV chronic kidney disease with elevated urinary albumin excretion rates in 21 countries worldwide (not considering whether type 2 diabetes is associated with it), primarily assessing the differences in efficacy and safety given to Dagley net 10 mg and placebo on a standard basis. The compound endpoint of the study was a deterioration or death of kidney function, defined as a continuous decline of more than 50% of eGFR, progressing to end-stage renal disease, cardiovascular death, and kidney death. Details of the study will be released at a medical conference soon, and AstraZeneca will immediately begin communication with regulators around the world to discuss the application for a listing.On September 16, 2019, the FDA granted Dagly net fast track eligibility to delay progression in renal failure and prevent cardiovascular and kidney death risk in patients with chronic kidney disease. A listing application for Dagrid's net treatment for heart failure has been submitted and has been reviewed as a priority by the FDA, as well as in the European Union and several regions. (Medical Rubik's Cube)